SCHEMBL899258

SCHEMBL899258

CCOCCn1cc[n+](C)c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 1/20 0.53
APAF1 O14727 1/20 0.53
NPC1 O15118 1/20 0.53
PLA2G1B P04054 1/20 0.53
HSP90AA1 P07900 1/20 0.53
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
ATG4B Q9Y4P1 1/20 0.53
FDPS P14324 2/20 0.35
LMNA P02545 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PON1 P27169 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6116136 0.98 SMN1; SMN2 (0.56) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL16674008 0.90 SMN1; SMN2 (0.53) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL2520923 0.89 SMN1; SMN2 (0.59) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL12936199 0.89 SMN1; SMN2 (0.58) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL2519180 0.87 SMN1; SMN2 (0.62) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Hydrochloric Acid SCHEMBL16713772 0.87 SMN1; SMN2 (0.56) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL12936202 0.87 SMN1; SMN2 (0.56) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL17418620 0.84 SMN1; SMN2 (0.40) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL4893845 0.83 MEN1 (0.47) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL26695497 0.83 SMN1; SMN2 (0.51) SMN1; SMN2MEN1APAF1NPC1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921589-B2 Electrolyte formulations MERCK PATENT GMBH (DE) 2014-12-30 US claimed
US-8864883-B2 Surface treatments for dessicant media in a water recovery device Z124 (KY) 2014-10-21 US claimed
US-8829201-B2 Electrolyte Formulations MERCK PATENT GMBH (DE) 2014-09-09 US claimed
US-8808424-B2 Apparatus and method for removing CO2 from a production plant discharge MUNTERS CORPORATION (US) 2014-08-19 US claimed
EP-2673068-A1 Apparatus and method for removing co2 from a production plant discharge Munters Corporation (US) 2013-12-18 EP claimed
US-20130319022-A1 SURFACE TREATMENTS FOR DESSICANT MEDIA IN A WATER RECOVERY DEVICE Z124 (KY) 2013-12-05 US claimed
US-20120318360-A1 Electrolyte Formulations MERCK PATENT GMBH (DE) 2012-12-20 US claimed
US-20120204717-A1 APPARATUS AND METHOD FOR REMOVING CO2 FROM A PRODUCTION PLANT DISCHARGE MUNTERS CORPORATION (US) 2012-08-16 US claimed
WO-2012109547-A1 APPARATUS AND METHOD FOR REMOVING CO2 FROM A PRODUCTION PLANT DISCHARGE MUNTERS CORPORATION (US) 2012-08-16 WO claimed
US-20110247494-A1 LIQUID SORBANT, METHOD OF USING A LIQUID SORBANT, AND DEVICE FOR SORBING A GAS VTU Holding GmbH. (AT) 2011-10-13 US claimed
US-20250122323-A1 ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-04-17 US disclosed
US-20250122322-A1 ZWITTERIONIC COMPOUND, AND BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANATE COMPOSITION CONTAINING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, CURED PRODUCT AND METHOD FOR MANUFACTURING SAME, AND CARBONATE COMPOUND KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-04-17 US disclosed
CN-117946544-B Graphene premix, coating composition, and coated article 宣伟(南通)涂料有限公司 2024-12-17 CN disclosed
CN-117946544-A Graphene premix, coating composition, and coated article 宣伟(南通)涂料有限公司 2024-04-30 CN disclosed
CN-117813334-A Onium salt, blocking agent dissociation catalyst for blocking isocyanate, blocked isocyanate composition containing blocking agent dissociation catalyst, thermosetting resin composition, cured product, and method for producing same 广荣化学株式会社 2024-04-02 CN disclosed
US-20110247494-A1 LIQUID SORBANT, METHOD OF USING A LIQUID SORBANT, AND DEVICE FOR SORBING A GAS VTU Holding GmbH. (AT) 2011-10-13 US disclosed
WO-2011085965-A1 ELECTROLYTE FORMULATIONS MERCK PATENT GMBH (DE) 2011-07-21 WO disclosed
WO-2011085964-A1 ELECTROLYTE FORMULATIONS MERCK PATENT GMBH (DE) 2011-07-21 WO disclosed
WO-2011085967-A1 COMPOUNDS CONTAINING PERFLUOROALKYL-CYANO-ALKOXY-BORATE ANIONS OR PERFLUOROALKYL-CYANO-ALKOXY-FLUORO-BORATE ANIONS MERCK PATENT GMBH (DE) 2011-07-21 WO disclosed
US-20060186419-A1 Light-emitting device KABUSHIKI KAISHA TOSHIBA (JP) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120318360-A1 Electrolyte Formulations NHERF1, HCN4, DDT SMN1; SMN2 4519/4885MEN1 1923/4885APAF1 4563/4885
US-20250122322-A1 ZWITTERIONIC COMPOUND, AND BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANATE COMPOSITION CONTAINING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, CURED PRODUCT AND METHOD FOR MANUFACTURING SAME, AND CARBONATE COMPOUND RCC1, KDM2B, RB1 SMN1; SMN2 2224/4885MEN1 257/4885APAF1 4029/4885
US-20250122323-A1 ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR KDM2B, O60361, IDH3B SMN1; SMN2 2709/4885MEN1 1391/4885APAF1 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.